Murtagh Fliss E M, Marsh James E, Donohoe Paul, Ekbal Nasirul J, Sheerin Neil S, Harris Fiona E
Department of Palliative Care and Policy, King's College Hospital, London, Se5 9RJ, UK.
Nephrol Dial Transplant. 2007 Jul;22(7):1955-62. doi: 10.1093/ndt/gfm153. Epub 2007 Apr 4.
The number of elderly patients with chronic kidney disease (CKD) stage 5 is steadily increasing. Evidence is needed to inform decision-making for or against dialysis, especially in those patients with multiple comorbid conditions for whom dialysis may not increase survival. We therefore compared survival of elderly patients with CKD stage 5, managed either with dialysis or conservatively (without dialysis), after the management decision had been made, and explored which of several key variables were independently associated with survival.
A retrospective analysis of the survival of all over 75 years with CKD stage 5 attending dedicated multidisciplinary pre-dialysis care clinics (n=129) was performed. Demographic and comorbidity data were collected on all patients. Survival was defined as the time from estimated GFR<15 ml/min to either death or study endpoint.
One- and two-year survival rates were 84% and 76% in the dialysis group (n=52) and 68% and 47% in the conservative group (n=77), respectively, with significantly different cumulative survival (log rank 13.6, P<0.001). However, this survival advantage was lost in those patients with high comorbidity scores, especially when the comorbidity included ischaemic heart disease.
In CKD stage 5 patients over 75 years, who receive specialist nephrological care early, and who follow a planned management pathway, the survival advantage of dialysis is substantially reduced by comorbidity and ischaemic heart disease in particular. Comorbidity should be a major consideration when advising elderly patients for or against dialysis.
老年慢性肾脏病(CKD)5期患者的数量正在稳步增加。需要证据来为透析决策提供参考,特别是对于那些合并多种疾病且透析可能无法提高生存率的患者。因此,我们比较了老年CKD 5期患者在做出透析或保守治疗(不透析)决策后的生存率,并探讨了几个关键变量中哪些与生存率独立相关。
对所有75岁以上就诊于专门的多学科透析前护理诊所的CKD 5期患者(n = 129)的生存情况进行回顾性分析。收集了所有患者的人口统计学和合并症数据。生存时间定义为从估计肾小球滤过率(GFR)<15 ml/min到死亡或研究终点的时间。
透析组(n = 52)的1年和2年生存率分别为84%和76%,保守治疗组(n = 77)分别为68%和47%,累积生存率有显著差异(对数秩检验13.6,P < 0.001)。然而,在合并症评分高的患者中,这种生存优势丧失,尤其是当合并症包括缺血性心脏病时。
在75岁以上的CKD 5期患者中,那些早期接受专科肾脏护理并遵循计划管理路径的患者,合并症尤其是缺血性心脏病会显著降低透析的生存优势。在为老年患者提供透析建议时,合并症应是主要考虑因素。